Indian companies supplied 47% of US generic prescriptions. Taxing them would first raise America’s medicine bill.
On April 2, the White House announced a 100% Section 232 tariff on imported patented pharmaceutical products and ingredients.
But it drew a clear line:
→ Patented pharmaceutical imports: 100% tariff
→ Generics, biosimilars, and related ingredients: exempt for now
→ The generic exemption: reviewed within one year
While people read this as India escaping the tariff, I think it's America acknowledging its own dependence.
The FDA says more than 90% of prescriptions filled in the US are generics. Indian companies supplied 47% of those generic prescriptions in 2022, representing four out of every ten US prescriptions overall.
Indian-made medicines generated an estimated $219 billion in savings for the U.S. healthcare system in 2022. Washington can draw a tariff wall around patented drugs while trying to push more production home.
Generics are different.
Taxing the pipe carrying America’s affordable medicines would hit patients, pharmacies, insurers, and hospitals before it seriously reduced US dependence on India.
That is structural necessity, not generosity.
Pharma remains one of my strongest sector convictions for 2026. But the exemption is not permanent. The one-year review is the number I am watching.
Can America rebuild enough capacity within one year to tax the medicines filling 90% of its prescriptions?
(Views shared here are for educational and informational purposes only and should not be considered investment advice.)
